NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

BofA cites customer engagment for Cardlytics stock

EditorEmilio Ghigini
Published 20/06/2024, 14:12
CDLX
-

On Thursday, BofA Securities resumed its coverage on Cardlytics (NASDAQ:CDLX) stock, issuing a Neutral rating and setting a price target of $11.00. Cardlytics, known for its targeted promotional deals offered through banking applications and websites, leverages its access to anonymized card transaction data from one in every two transactions in the United States. This access is made possible through its partnerships with over 2,000 financial institutions.

The company's business model is noted for having high barriers to entry, primarily due to its strong relationships with financial institutions which make it difficult for competitors to gain similar traction.

Despite this advantage, BofA Securities points out that Cardlytics' long-term growth is contingent on its ability to attract more advertising dollars from brands focused on performance and brand advertising. This challenge is amplified by the company's limited control over data usage and product design.

The firm highlights the difficulties Cardlytics may face in product innovation due to the regulated and risk-averse nature of its financial institution partners. These factors could potentially slow down the company's ability to innovate and adapt to the rapidly changing digital advertising landscape.

Bofa Securities' reinstated coverage comes with the perspective that while Cardlytics holds a valuable data asset and is well-protected from competition, its growth prospects may be tempered by the inherent challenges in its operating environment. The $11.00 price target reflects this cautious outlook on the company's future performance.

In other recent news, Cardlytics had a robust start to the year with its first-quarter earnings revealing a 12% increase in billings and a significant rise in adjusted contribution. This is the first time the company reported a positive adjusted EBITDA for a first quarter.

Cardlytics also raised $50 million in cash and made strategic moves to improve its capital structure. Despite a negative operating cash flow, the company expects it to turn positive in the second half of the year.

Northland initiated coverage on Cardlytics, assigning an Outperform rating and setting a price target of $14.00, reflecting confidence in Cardlytics' potential in the digital advertising sector.

The company's revenue growth was noted in both the U.S. and U.K., with the U.K. experiencing a 56% increase. For the upcoming second quarter, Cardlytics forecasts billings between $115 million and $126 million, and revenue estimates between $73 million and $81 million.

In addition to its financial growth, Cardlytics is investing in sales and technology, including the development of a self-serve platform for advertisers and the expansion of the Bridg retail media network. These are the recent developments in the company's journey.

InvestingPro Insights

InvestingPro data highlights the current financial landscape for Cardlytics (NASDAQ:CDLX). With a market capitalization of $400.26 million, the company's valuation reflects the challenges noted by analysts. The adjusted P/E ratio for the last twelve months as of Q1 2024 stands at -5.17, indicating that investors are currently valuing the company's earnings negatively. This is in line with the InvestingPro Tips that suggest analysts do not expect the company to be profitable this year. Additionally, the company's stock has experienced significant price volatility, with a 46.06% decline over the last three months, further emphasizing the cautious stance investors may take.

Despite these challenges, Cardlytics' financial health shows some positives. The company's liquid assets exceed its short-term obligations, which may provide some buffer against financial stress. Moreover, the company's revenue has seen growth of 5.95% over the last twelve months as of Q1 2024, showing that the business is still expanding its top line.

For readers considering an investment in Cardlytics, it may be beneficial to explore the additional 8 InvestingPro Tips available at InvestingPro for a more comprehensive analysis. Furthermore, those interested in a deeper dive can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing access to exclusive insights and data that can help in making informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.